atrs stock price

What is ATR stock indicators?

Main ATR Indicator And Strategies FAQ

• What is the ATR Indicator? The ATR Indicator, or Average True Range indicator, is an indicator that measures volatility. ...
• How to profit from the ATR Indicator? There are several ways to profit from using the ATR. ...
• How can we find breakout moves using the ATR Indicator? ...

How to use ATR for stop loss in trading?

• Price breakout of highs and you set a limit order to go long at $74.28
• Since you are using a limit order, you need to use the last printed candlesticks ATR reading (red arrow)
• You set the stop loss at 1 x ATR = .19 or 74.28-.19 = $74.09

What is ATR stand for?

ATR. Registered Art Therapist. ATR-BC. Registered Art Therapist - Board Certified.

What is trading ATR?

The TR for a given trading period is the greatest of the following:

• Current high minus the previous close
• Current low minus the previous close
• Current high minus the current low

See more

Should I buy or sell Antares Pharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last twelve months. There are currently 5 hold ratin...

What is Antares Pharma's stock price forecast for 2022?

5 equities research analysts have issued 12-month price targets for Antares Pharma's stock. Their forecasts range from $5.60 to $5.60. On average,...

How has Antares Pharma's stock price performed in 2022?

Antares Pharma's stock was trading at $3.57 at the start of the year. Since then, ATRS shares have increased by 56.6% and is now trading at $5.59....

Are investors shorting Antares Pharma?

Antares Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 4,780,000 shares, a decr...

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Antar...

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) posted its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported ($0.0...

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma issued an update on its FY 2022 earnings guidance on Thursday, March, 31st. The company provided earnings per share (EPS) guidance o...

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people: Mr. Robert F. Apple , CEO, Pres & Director (Age 56, Pay $1M) Mr. Fred M. Powell...

What is Paul K. Wotton's approval rating as Antares Pharma's CEO?

5 employees have rated Antares Pharma CEO Paul K. Wotton on Glassdoor.com . Paul K. Wotton has an approval rating of 18% among Antares Pharma's em...

Is Antares Pharma stock a Buy, Sell or Hold?

Antares Pharma stock hasn't recieved a clear consensus rating. The average rating score is and is based on 2 buy ratings, 2 hold ratings, and 0 sel...

What was the 52-week low for Antares Pharma stock?

The low in the last 52 weeks of Antares Pharma stock was 3.11. According to the current price, Antares Pharma is 179.74% away from the 52-week low.

What was the 52-week high for Antares Pharma stock?

The high in the last 52 weeks of Antares Pharma stock was 5.60. According to the current price, Antares Pharma is 99.82% away from the 52-week high.

What are analysts forecasts for Antares Pharma stock?

The 4 analysts offering price forecasts for Antares Pharma have a median target of 5.30, with a high estimate of 5.60 and a low estimate of 5.00. T...

Atrium European Real Estate Limited -- Moody's affirms Atrium European Real Estate's Baa3 ratings, outlook stable, Ba2 rating assigned to hybrid notes

Atrium European Real Estate Limited -- Moody's announces completion of a periodic review of ratings of Atrium European Real Estate Limited

Rating Action: Moody's affirms Atrium European Real Estate's Baa3 ratings, outlook stable, Ba2 rating assigned to hybrid notesGlobal Credit Research - 22 Apr 2021Frankfurt am Main, April 22, 2021 -- Moody's Investors Service (Moody's) has today affirmed the Baa3 long-term issuer rating and the Baa3 senior unsecured ratings of Atrium European Real Estate Limited (Atrium).

Antares Pharma (NASDAQ:ATRS) Price Target and Consensus Rating

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Atrium European Real Estate LimitedGlobal Credit Research - 15 Apr 2021Frankfurt am Main, April 15, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Atrium European Real Estate Limited and other ratings that are associated with the same analytical unit.

Analyst Price Target Consensus

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).

Analyst Ratings By Month

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Average Share Price and Price Target by Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Antares Pharma (NASDAQ:ATRS) Analyst Ratings Frequently Asked Questions

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.

Signals & Forecast

According to the issued ratings of 2 analysts in the last year, the consensus rating for Antares Pharma stock is Buy based on the current 2 buy ratings for ATRS. The average twelve-month price target for Antares Pharma is $6.00 with a high price target of $7.00 and a low price target of $5.00. Learn more on ATRS's analyst rating history

Support, Risk & Stop-loss

A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 8.20%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal.

Is Antares Pharma stock A Buy?

Antares Pharma finds support from accumulated volume at $3.42 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

Insiders are positive buying more shares than they are selling in Antares Pharma

Antares Pharma holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

About Antares Pharma

In the last 100 trades there were 3.85 million shares bought and 2.24 million shares sold. The last trade was done 103 days ago by Volkart Carmen B who bough 55.92 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.

Golden Star Signal

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.

Top Fintech Company

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!